Curis, Inc. (CRIS)

NASDAQ: CRIS · IEX Real-Time Price · USD
15.28
-0.62 (-3.90%)
Apr 12, 2024, 4:30 PM EDT - Market closed
-3.90%
Market Cap 90.06M
Revenue (ttm) 10.02M
Net Income (ttm) -47.41M
Shares Out 5.89M
EPS (ttm) -8.96
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 8,007
Open 15.91
Previous Close 15.90
Day's Range 14.92 - 16.24
52-Week Range 0.38 - 17.49
Beta 3.76
Analysts Strong Buy
Price Target 37.33 (+144.31%)
Earnings Date May 2, 2024

About CRIS

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with r... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Aug 1, 2000
Employees 49
Stock Exchange NASDAQ
Ticker Symbol CRIS
Full Company Profile

Financial Performance

In 2023, Curis's revenue was $10.02 million, a decrease of -1.37% compared to the previous year's $10.16 million. Losses were -$47.41 million, -16.34% less than in 2022.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for CRIS stock is "Strong Buy." The 12-month stock price forecast is $37.33, which is an increase of 144.31% from the latest price.

Price Target
$37.33
(144.31% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

LEXINGTON, Mass. , April 5, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced ...

9 days ago - PRNewsWire

Curis to Present at Upcoming Healthcare Conferences in April

LEXINGTON, Mass. , April 4, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced ...

10 days ago - PRNewsWire

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Curis, Inc. (NASDAQ: CRIS)

NEW YORK , April 2, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Curis, Inc. (NASDAQ: CRIS) on behalf of the company's shareholders.  The investigation seeks to dete...

12 days ago - PRNewsWire

Curis Provides Fourth Quarter 2023 Business Update

Emavusertib data presented at ASH showed 3 of 5 patients achieved CR in R/R PCNSL Expansion of clinical sites in US and Europe in progress Cash runway into 2025 Management to host conference call toda...

2 months ago - PRNewsWire

Curis to Release Fourth Quarter 2023 Financial Results and Hold Conference Call on February 8, 2024

LEXINGTON, Mass. , Feb. 1, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhib...

2 months ago - PRNewsWire

Curis Announces Initial Combination Study Data from its TakeAim Lymphoma Study

LEXINGTON, Mass. , Dec. 12, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhi...

4 months ago - PRNewsWire

Curis Presented Clinical Data from the TakeAim Leukemia Study at the 2023 ASH Conference

LEXINGTON, Mass. , Dec. 11, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhi...

4 months ago - PRNewsWire

Curis Announces Three Presentations at ASH

LEXINGTON, Mass. , Dec. 6, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhib...

4 months ago - PRNewsWire

Curis Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in Melanoma

LEXINGTON, Mass. , Dec. 5, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhib...

4 months ago - PRNewsWire

Curis's stock rises as analysts see ‘the next Pharmacyclics'

Shares of Curis Inc. CRIS, +4.23% gained nearly 6% premarket on Friday after Truist Securities analysts initiated coverage of the cancer-focused biotech company with a buy rating.

5 months ago - Market Watch

Curis Provides Third Quarter 2023 Business Update

Continued progress on the development of emavusertib Strong balance sheet with $68.5 million in cash and investments; cash runway into 2025 Management to host conference call today at 8:30 a.m. ET LEX...

5 months ago - PRNewsWire

Curis to Release Third Quarter 2023 Financial Results and Hold Conference Call on November 2, 2023

LEXINGTON, Mass. , Oct. 26, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor for ...

6 months ago - PRNewsWire

Curis Announces Date for the 2nd Symposium on IRAK4 in Cancer

Symposium hosted by Guillermo Garcia-Manero, M.D. and Eric Winer, M.D.

7 months ago - PRNewsWire

Curis to Present at Upcoming Healthcare Conferences in September

LEXINGTON, Mass. , Sept. 6, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available small molecule IRAK4 inhibitor for t...

7 months ago - PRNewsWire

Curis Provides Second Quarter 2023 Business Update

Removal of partial clinical hold – enrolling patients at confirmed RP2D in the TakeAim Leukemia Study Enrolling patients in the TakeAim Lymphoma Study in combination with ibrutinib Strong balance shee...

9 months ago - PRNewsWire

Curis to Release Second Quarter 2023 Financial Results and Hold Conference Call on August 3, 2023

LEXINGTON, Mass. , July 27, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor for ...

9 months ago - PRNewsWire

FDA Removes Partial Clinical Hold on TakeAim Leukemia Study RP2D Established at 300 mg BID

LEXINGTON, Mass. , July 6, 2023 /PRNewswire/ -- Curis, Inc., (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib, an orally available small molecule triple target inhibit...

10 months ago - PRNewsWire

Curis Announces $15.1 Million Registered Direct Offering

LEXINGTON, Mass. , July 6, 2023 /PRNewswire/ -- Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib, a triple target inhibitor (IRAK4, FLT3 and CLK) for the t...

10 months ago - PRNewsWire

Curis Provides First Quarter 2023 Business Update

Company expects to discuss lifting of partial clinical hold on emavusertib with FDA in Q3 Curis strengthens executive team with appointment of industry veteran Jonathan Zung, Ph.D. as Chief Developmen...

1 year ago - PRNewsWire

Curis to Release First Quarter 2023 Financial Results and Hold Conference Call on May 4, 2023

LEXINGTON, Mass. , April 27, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced...

1 year ago - PRNewsWire

Curis Provides Fourth Quarter 2022 Business Update

Curis completes enrollment of the 9 additional patients requested by FDA ahead of schedule in its TakeAim Leukemia study Management to host conference call today at 8:30 a.m. ET LEXINGTON, Mass.

1 year ago - PRNewsWire

Curis Reschedules Fourth Quarter 2022 Business Update and Conference Call

LEXINGTON, Mass. , March 8, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced today ...

1 year ago - PRNewsWire

Curis to Release Fourth Quarter 2022 Financial Results and Hold Conference Call on March 9, 2023

LEXINGTON, Mass. , March 2, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced ...

1 year ago - PRNewsWire

Curis Announces Additional Encouraging Clinical Data from TakeAim Leukemia Study of emavusertib (CA-4948) in Monotherapy R/R AML and hrMDS

29% CR rate observed in R/R AML patients with FLT3 mutation 22% CR/CRh rate observed in R/R AML with spliceosome mutation 45% ORR observed in R/R hrMDS patients with spliceosome mutation Curis to revi...

1 year ago - PRNewsWire

Curis to Host Webcast to Discuss Updated Emavusertib Clinical Data in Leukemia

Curis to review results during conference call, featuring commentary  by Dr. Eric Winer, M.D., Dana-Farber Cancer Institute, on Monday, December 12 at 10:00 a.m.

1 year ago - PRNewsWire